NFKB1 and COVID-19: While there are ongoing clinical trials withJAKi for treating patients with COVID-19, our analyses suggest that combining a JAKi, such asRuxolitinib, with modifiers of NF-κB signaling, for example anti-viral agents (e.g.Remdesivir) or TNF antagonists, may be a better therapeutic approach than monotherapy alone.Because of concerns regarding the use of JAKi in a disease with a propensity to thrombosis,combining a JAKi with a second agent may permit use of lower doses of both drugs, potentiallyreducing thrombotic adverse effects and reducing risks of viral replication.